港股午评|恒生指数早盘涨1.01% CRO概念股涨幅居前

Group 1 - The Hang Seng Index rose by 1.01%, gaining 268 points to close at 26,877 points, while the Hang Seng Tech Index increased by 0.38% [1] - Alibaba's stock increased by 3.5%, with its Q&A model downloads surpassing 700 million, indicating potential acceleration in Alibaba Cloud's revenue growth [1] - CRO concept stocks saw significant gains, with WuXi AppTec's net profit expected to double, leading to a potential "Davis Double" effect; WuXi AppTec rose by 7.85%, Kelun Pharmaceutical by 5%, and CRISPR Therapeutics by 6% [1] - Rongchang Biologics surged by 11.64% after authorizing its dual-antibody product RC148 to AbbVie, with a total transaction value potentially reaching $5.6 billion [1] - Lithium carbonate futures prices continued to rise, boosting Ganfeng Lithium's stock by 4% and Tianqi Lithium's by 2.8% [1] - AI healthcare concept stocks mostly advanced, with NVIDIA partnering with Eli Lilly to invest $1 billion in a joint laboratory; Medlinker rose by 6% and Crystal Tech Holdings by 5.87% [1] - Ark Health's stock skyrocketed by 36% after collaborating with Tencent Health for digital upgrades in "AI + chronic disease management" [1] - Fuhong Hanlin's stock increased by over 8%, with the first release of Phase II data for its broad-spectrum anti-tumor PD-L1 ADC HLX43 in esophageal squamous cell carcinoma [1] - Yiming Anke's stock rose by over 9% after receiving approval for clinical trials of IMM01 for atherosclerosis treatment [1] Group 2 - WanGuo Gold Group's stock increased by 4.6%, with gold prices rising, leading to a month-to-date gain of over 30% [2] - Three new stocks were listed, with Zhaoyi Innovation's stock rising by 40% on its debut, being a domestic leader in storage chips and MCUs; BBSB INTL surged by 65%, and Hongxing Cold Chain increased by 4% [2] Group 3 - Commercial aerospace concept stocks collectively adjusted, with Goldwind Technology's stock dropping over 13% at one point and more than 6% at midday [3]